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Background: Hydroxyurea (HU) reduces major complications associated with sickle cell disease in part because of the induction
of fetal hemoglobin. However, because of its antiproliferative property, its long-term use may impair immunity. Zileuton, a
derivative of HU, also induces fetal hemoglobin and has antiinflammatory properties, a feature that can reduce the risk of
sickling. Our goal was to investigate the capacity of both drugs to modulate the secretion of interleukin-2 (IL-2), a regulatory
cytokine for immune responses.
Methods: Spleen cells obtained from 11 4-month-old C57BL/6 female mice were incubated without and with 10 lg/mL HU or
zileuton, 2.5 lg/mL concanavalin A (ConA), 20 lg/mL phytohemagglutinin (PHA), and 50 ng/mL anti-CD3 antibody for 12-48 h.
IL-2 was measured in the supernatant by enzyme-linked immunosorbent assay and cell proliferation by 3H-thymidine uptake.
Results: While HU reduced lymphocyte proliferation in response to mitogens (P<0.05), zileuton did not. Baseline IL-2
concentration and PHA-induced IL-2 were not significantly affected by either drug. Contrary to what we expected, while HU
increased IL-2 supernatant levels 1.17-fold to 6.5-fold in anti-CD3 antibody–treated cells (P<0.05), zileuton decreased them 35%-
65% (P<0.05). Zileuton likely reduced IL-2 levels by inhibiting 5-lipoxygenase, hence leukotriene B4 production, an IL-2 inducer.
HU did not decrease IL-2 secretion likely because of its lack of effect on mRNA and protein synthesis.
Conclusion: Modulation of IL-2 secretion by zileuton and/or reduced lymphocyte proliferation by HU may impair the immune
response of patients with sickle cell disease but may also be beneficial by attenuating inflammation independently of fetal
hemoglobin induction.
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INTRODUCTION
Sickle cell anemia or sickle cell disease (SCD) is the
most common genetic disorder diagnosed in individuals of
African ancestry and a subgroup of people from India, the
Mediterranean region, and the Middle East.1,2 The disease
is caused by a point mutation (GTGGAG) in the gene
that codes the b-globin chain of hemoglobin, leading to a
substitution of glutamic acid by valine at the sixth position.
This simple single amino acid change causes hemoglobin
to polymerize upon loss of oxygen in the tissue, leading to
distortion in the shape of red blood cells (RBCs). The
disease is characterized by frequent episodes of vaso-
occlusive pain crisis because of increased adhesion of the
sickle-shaped RBCs along with white blood cells and
platelets to endothelial cells.1 Other complications include
RBC hemolysis, a defective spleen, impaired cell-mediat-
ed and natural immunity, increased risk of pneumococcal
infection, acute chest syndrome, physical growth retarda-
tion in children, and multiorgan failure (bones, lungs,
brain, and kidneys).2-4 Disease severity is variable and
depends in part on fetal hemoglobin levels.5 SCD
management often involves frequent blood transfusions
that unfortunately induce iron overload and penicillin
prophylaxis.6
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ORIGINAL RESEARCH
In the early 1990s, hydroxyurea (HU), a drug often used to
treat chronic myelogenous leukemia,7 was shown to reduce
the frequency of pain crises and associated complications
in patients with SDC in part because of the induction of fetal
hemoglobin through nitric oxide production.8-11 Specifically,
patients treated with HU required less frequent hospitaliza-
tion because of vasoocclusive pain crises and fewer blood
transfusions.9 They also had fewer episodes of new and
recurrent neurologic disorders, lower white blood cell
counts, fewer cell adhesion molecules, and lower mortality.9
However, as an antiproliferative agent, HU may induce
neutropenia, anemia, and thrombocytopenia because of
bone marrow suppression, delayed wound healing, diar-
rhea, and growth retardation, side effects that are undesir-
able, especially in young children.8 The mechanism of HU’s
antiproliferative property relies on its capacity to inactivate
ribonucleotide reductase by binding to subunit B2 of the
enzyme.12 Ribonucleotide reductase is a key enzyme in the
pathway of DNA synthesis and cell proliferation because it is
required for the biosynthesis of deoxyribonucleotides from
ribonucleosides.12 Its long-term use may also impair
immune responses because of the rapid proliferation of
the immune cells, an effect that can further compromise the
immune response of patients with SCD and potentially
increase the risk of infection.13,14 In fact, a 2014 study
conducted by Lederman et al suggested that HU in children
with SCD decreased the absolute number of leukocytes,
CD4þ cells, and memory CD4þ cells and delayed the
production of protective levels of measles antibodies
following vaccination.15 Moreover, HU has also been linked
to leukemia and mutations such as those with 17p deletion
and may induce male infertility.16-18
Zileuton (sold as Zyflo), an HU derivative antiinflammatory
drug used for the treatment of asthma, induces fetal
hemoglobin synthesis as efficiently as HU.19-21 Zileuton’s
mechanism of action in asthma relies on its capacity to
inhibit 5-lipoxygenase (in various cell types, specifically
macrophages, neutrophils, and eosinophils), the key
enzyme that leads to the production of leukotriene A4 and
subsequently leukotriene B4 (LTB4), a mediator of inflam-
mation.19,20 LTB4 is an inducer of interleukin-2 (IL-2) and
therefore modulates lymphocyte proliferation in response to
mitogens.22 As with any drug, zileuton also induces certain
side effects including nausea, skin rash, diarrhea, insomnia,
and elevated liver transaminases but has not been shown to
decrease total white blood cell counts (it does not induce
bone marrow suppression).20
The structures of HU, zileuton, and the parent compound
urea are shown in Figure 1. Based on the charts, HU is
nothing more than a urea molecule with a hydroxyl (OH)
group attached to one of the nitrogens. Zileuton differs from
HU by having a molecule N-(1-Benzo[b]thien-2-ylethyl) with
2 rings and a sulfur molecule attached to the same nitrogen
as OH. Therefore, it is also called N-(1-Benzo[b]thien-2-
ylethyl)-1-hydroxyurea. The hydroxyl group in HU is very
likely responsible for its inhibitory effect (inactivation of the
subunits) of ribonucleotide reductase, whereas the N-(1-
Benzo[b]thien-2-ylethyl) group is likely responsible for
zileuton’s effect on 5-lipoxygenase.
IL-2, a cytokine secreted by activated CD4þ T lympho-
cytes, naive CD8þ cells, and dendritic cells, plays crucial
roles in several immune functions, including regulation of
delayed-type hypersensitivity and cell proliferation, activa-
tion of CD8þ T cells and natural killer cells, and induction of
other cytokines such as interferon-gamma (IFN-c).23,24
Moreover, IL-2 induces the differentiation of monocytes to
dendritic cells, the most potent antigen-presenting cells,
and is a source of proinflammatory cytokines including IL-
1b, tumor necrosis factor-alpha (TNF-a), and IL-12.25
Reduced IL-2 secretion may therefore impair the immune
response by various mechanisms and increase the risk of
certain types of infections.
Although HU and zileuton induce fetal hemoglobin
synthesis, little is known about their possible differential
effect on IL-2 secretion. This question is important in the
management of SCD—specifically in children—because of
the role of IL-2 in modulating immune function, including the
production of inflammatory cytokines such as TNF-a.
Although moderate inflammation is required for pathogen
killing, chronic inflammation is a risk factor for many chronic
diseases, and inflammation appears to either trigger or
worsen pain crises.26,27 Moreover, infections are common in
children with SCD, and infections contribute to the risk of pain
crisis.3,4 This study was designed to examine the effects of
HU and zileuton on IL-2 secretion and whether the effects, if
any, are exerted through modulation of cell proliferation.
METHODS
Reagents were purchased from the following vendors:
concanavalin A (ConA) and b-mercaptoethanol from Sigma-
Aldrich; RPMI 1640 medium with 25 mmol/L HEPES, fetal
calf serum (FCS), nonessential amino acids, sodium
pyruvate, penicillin/streptomycin, phytohemagglutinin
(PHA), and L-glutamine from GIBCO; 3H-thymidine (6.7 Ci
or 247.9 GBq/mmol) from Dupont NEN; CytoScint scintilla-
tion cocktail from ICN; anti-CD3 antibody from BD Pharmin-
gen; and zileuton from the University of South Alabama
Pharmacy.
Eleven 4-week-old C57BL/6 healthy female mice were
purchased from Charles River Laboratories and housed at
the Louisiana State University Health Sciences Center
(LSUHSC) vivarium for 3 months. They were given a
semipurified (AIN93) diet purchased from Research Diets
Inc. Mice had free access to their feeds and sterile water 24
h/day. The mice did not receive any drugs. The light-to-dark
cycle was 12 h, and the environmental conditions were 228C
with 56% humidity. The study was approved by the LSUHSC
Institutional Animal Care and Use Committee.
Mice were subjected to ether inhalation for 60 seconds,
and spleens were removed under sterile conditions. Single
cell suspensions were prepared from each spleen by
standard techniques, and cell viability was assessed by
trypan blue exclusion test. Viable cells (23 106) were mixed
with either HU or zileuton (10 lg/mL) without and with 2.5
lg/mL ConA, 50 ng/mL anti-CD3 antibody, and 20 lg/mL
PHA in 123 75 mm sterile culture tubes. These doses were
used in a pretest and were found optimal for modulating
spleen cell proliferation. The culture medium was com-
posed of 0.1 mmol/L nonessential amino acids, 1 mmol/L
sodium pyruvate, 50 lmol/L b-mercaptoethanol, 50,000
units penicillin/L, 50 mg streptomycin/L, and 2 mmol/L L-
glutamine in RPMI 1640. The culture medium was also
supplemented with either 2% or 5% of FCS. The purpose of
the low FCS (2%) was to limit the concentration of growth
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factors that could mask the immunomodulatory effects of
HU and zileuton. For baseline (no drug) IL-2 secretion and
cell proliferation, culture medium was added to bring the
total volume per tube to 1 mL.
Macrocultures were incubated at 378C, 5% CO2 in a
humidified atmosphere for 12 h, 24 h, and 48 h. At the end
of the incubation period, tubes were centrifuged at 2,000
rpm and 48C for 10 min. The supernatant was collected and
immediately frozen at 708C until used for measurement of
IL-2 by enzyme immunoassay with kits purchased from R&D
Systems. The methods described in the brochure supplied
with the reagents were carefully followed, and all tests were
performed in duplicate.
To rule out the possibility that changes, if any, in IL-2
secretion in cultures incubated with either drug were
because of an effect on cell proliferation (the rate of DNA
synthesis), microcultures were also prepared in culture
medium supplemented with 10 lg/mL HU or zileuton in the
presence and absence of the same concentrations of
mitogens as for macroculture (see above). We transferred 2
3 105 cells/200 lL in triplicate to 96-well plates followed by a
48 h incubation at 378C, 5% CO2 in a humidified atmosphere,
and then pulsed with 1 lCi (37 Bq) per well for an additional
24 h. Cultures were harvested onto filters using a PHD Cell
Harvester (Cambridge Technology), and the radioactivity
incorporated into DNA was measured by counting each filter
dissolved in 2 mL CytoScint scintillation cocktail for 1 min in
an LKB Wallac model 1219 liquid scintillation counter.
Descriptive statistics (mean – SEM of 11 mice used
individually) and analysis of variance (ANOVA) were
calculated by a microstatistical program (MYSTAT v.2).
When ANOVA detected significant differences among the 3
types of cultures, a Tukey test was performed to identify test




In nonactivated cells, neither zileuton nor HU had any
effect on IL-2 secretion at any time point studied (Figures 2A
and 2B). When cells were incubated in 2% FCS-supple-
mented medium for 24 h and 48 h, HU did not significantly
affect ConA-induced IL-2 secretion compared to nonacti-
vated cultures (Figure 3A). When cells were incubated in 5%
FCS for 24 h and 48 h, HU also did not significantly affect IL-
2 levels. However, when cells were incubated for 12 h in the
same medium, HU slightly, although significantly, de-
creased ConA-induced IL-2 secretion (P<0.05) (Figure
3B). In contrast to HU, zileuton reduced ConA-induced IL-
2 secretion 45%-62% (P<0.05) (Figures 3A and 3B). The
only exception was cells that were incubated in 5% FCS-
supplemented medium for 12 h. In this case, zileuton did
not affect ConA-induced IL-2 secretion (Figure 3B).
When cells were activated by anti-CD3 antibody, HU
increased IL-2 secretion 1.17-fold to 6.5-fold (P<0.05), but
zileuton reduced it 35%-65% (P<0.05) (Figures 3C and 3D).
The only exception was the lack of IL-2 inhibition by zileuton
in cells incubated with anti-CD3 antibody in 5% FCS for 12
h. Also, HU slightly decreased IL-2 in cells incubated with
anti-CD3 antibody in 5% FCS for 12 h. In contrast to ConA-
and anti-CD3–treated cells, neither drug had a significant
modulatory effect on PHA-induced IL-2 secretion (data not
shown).
Figure 2. Effect of hydroxyurea (HU) and zileuton on
baseline interleukin-2 (IL-2) secretion in cells incubated in
(A) 2% fetal calf serum (FCS) and (B) 5% FCS for 12-48 h.
Values are means – SEM, n¼11. No significant difference
was observed between drugs.
Figure 1. Structures of hydroxyurea, zileuton, and the parent compound urea.
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IL-2 data for cells incubated with various drugs in 5%
FCS-supplemented medium were also analyzed as a
function of incubation period. In the presence of ConA, IL-
2 secretion in HU-treated and untreated cells followed the
same pattern: IL-2 levels peaked at 24 h and then
decreased below the levels observed at the 12 h time point
(P<0.05) (Figure 4A). For zileuton-treated cultures, IL-2
levels were highest at the 12 h time point but decreased at
the 24 h and 48 h time points (P<0.05) (Figure 4A). In anti-
CD3–treated cells, IL-2 decreased in zileuton-treated and
untreated cells with increasing incubation time (P<0.05)
(Figure 4B). In HU-treated cells, anti-CD3–induced IL-2
secretion increased with time, being lowest at 12 h and
highest at 48 h (P<0.05).
Cell Proliferation
As shown in Figure 5 and as expected, HU significantly
inhibited cell proliferation in all T cell mitogen-treated cultures
54%-79% (P<0.05), while zileuton had very little effect. In
ConA- and anti-CD3–treated spleen cells, the concentration
of FCS (2% in Figure 5A and 5% in Figure 5B) did not modify
the proliferative responses to HU and zileuton.
DISCUSSION
In the current study, we investigated the possible
differential effects of HU and zileuton on in vitro immune
function assessed by cell proliferation and IL-2 secretion by
spleen cells obtained from normal young adult mice. The
main reasons for conducting the study were to explore the
role of IL-2 in modulating both adaptive (T cell and B cell) and
natural immunities, the role of IL-2 in monocyte/macrophage
activation and subsequent induction of proinflammatory
cytokines that are required for pathogen killing, the require-
ment of cell proliferation for amplification of the immune
response once the host is exposed to pathogens or foreign
compounds, and the correlation between in vitro immune
responses assessed by lymphocyte proliferation and in vivo
immunity as in the case of protein-energy malnutrition.27-29
Our results suggest that HU does not inhibit ConA- or
anti-CD3–induced IL-2 secretion by murine spleen cells; in
fact, it tended to upregulate it. This finding was unexpected
Figure 3. Concentration of interleukin-2 (IL-2) in the supernatant of (A and B) concanavalin A
(ConA)-treated and (C and D) anti-CD3 antibody–treated murine spleen cells incubated
without and with either hydroxyurea (HU) or zileuton for 12-48 h. Values are means – SEM,
n¼11. With each mitogen and incubation period, bars followed by different letters are
significantly different: a>b>c, P<0.05. FCS, fetal calf serum.
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considering that HU is an antiproliferative agent as
previously reported and confirmed in our study.9,12,13
However, the results make sense because HU does not
interfere with mRNA and/or protein synthesis but rather with
DNA synthesis through inactivation of ribonucleotide reduc-
tase.12 In fact, a similar study conducted in 13 subjects
infected with human immunodeficiency virus and 10
controls also did not report any alteration of IL-2 secretion
by HU but reported a significant reduction in IFN-c
secretion.14 The decreased IFN-c was probably because
this cytokine is secreted mostly by CD8þ T cells in addition
to CD4þ T cells, natural killer cells, and dendritic cells;
therefore, the decrease could be related to non-CD4þ T
cells.30,31 In any case, normal or adequate induction of IL-2
is not sufficient to overcome the antiproliferative property of
HU because of continuous block of lymphocytes in the early
S phase of the cell cycle. Assuming that we can extrapolate
our data to an in vivo scenario, the lack of negative effect of
HU on IL-2 secretion may modulate the function of cells
involved in innate immunity such as natural killer cells,
monocytes, and macrophages in the early phase of an
infection. On the other hand, the continuous presence of HU
in blood may also compromise the adaptive immune
function because of impaired lymphocyte proliferation.
Despite the lack of inhibitory effect on cell proliferation,
zileuton significantly reduced IL-2 secretion in ConA- and
anti-CD3–treated cells. This observation may be explained
by the fact that this drug inhibits 5-lipoxygenase and hence
LTB4 production.20,21 LTB4 is known to upregulate IL-2
secretion and induce lymphocyte proliferation in response
to mitogens.23 Inhibition of LTB4 would reduce IL-2
secretion and may compromise adaptive immunity in
zileuton-treated subjects. However, decreased IL-2 may
also result in lower macrophage activation and hence in
reduced inflammatory cytokines. Additionally, reduced
inflammatory cytokines may attenuate the expression of
adhesion molecules such as CD36 and VLA-4 on blood
cells and thus on lung injury.
Interesting to note are the differences for HU and zileuton
in time-dependent changes in IL-2 secretion. In zileuton-
treated cells, IL-2 decreased with time, being lowest at 48 h,
suggesting that zileuton’s inhibitory effect was expressed
early during incubation. This finding is not surprising
because in the absence of drugs such as HU or zileuton,
IL-2 secretion is induced by mitogens within the first 24 h of
lymphocyte activation and then decreases during the
following 48-72 h.32
Figure 4. Effects of incubation time and treatment of
hydroxyurea and zileuton on interleukin-2 (IL-2) secretion
by (A) concanavalin A (ConA)-treated and (B) anti-CD3
antibody–treated murine spleen cells. Values are means –
SEM, n¼11. With each drug, bars with different letters are
significantly different: a>b>c, P<0.05. FCS, fetal calf serum.
Figure 5. 3H-thymidine incorporation into DNA in mitogen-
treated and untreated murine spleen cells incubated
without and with hydroxyurea (HU) or zileuton in (A) 2%
fetal calf serum (FCS)- and (B) 5% FCS-supplemented culture
medium. Values are means– SEM, n¼11. Bars with different
letters are significantly different: a>b, P<0.05. ConA,
concanavalin A; PHA, phytohemagglutinin.
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Despite the low IL-2 levels in the supernatant, zileuton did
not inhibit cell proliferation, suggesting that the amounts of
IL-2 in the supernatant were high enough to promote cell
proliferation. We do not believe that the low IL-2 levels in
zileuton-treated cells were the result of cell death because
of lack of inhibition of 3H-thymidine uptake (Figures 5A and
5B). Additionally, zileuton does not interfere with ribonucle-
otide reductase activity.
In summary, our data suggest that zileuton does not
inhibit cell proliferation but significantly inhibits IL-2 secre-
tion. In contrast, HU does the opposite. It appears that
zileuton may be beneficial in the management of SCD by 3
mechanisms: induction of fetal hemoglobin, reduction of
inflammation through low IL-2 secretion, and lack of bone
marrow suppression. In contrast, HU may modulate the risk
of SCD pain crisis through fetal hemoglobin production and
maintenance of IL-2 secretion, and hence adaptive immu-
nity. To our knowledge, this study is the first to show
different behaviors of normal murine splenic lymphocytes to
HU and zileuton with relation to IL-2 secretion and in parallel
cell proliferation.
Our study has the following limitations: the use of normal
rather than sickle cell mice, the in vitro rather than in vivo
study design, the lack of information on the effects of
zileuton on the management of SCD, and the lack of
information on the effects of both drugs on the risk of
sepsis. These issues are the focus of our next studies.
CONCLUSION
In conclusion, modulation of IL-2 secretion by zileuton
and/or reduced lymphocyte proliferation by HU may impair
the immune response and increase the risk of or the time
required to clear an infection. However, both may also be
beneficial in the management of SDC through modulation
of inflammation independently of fetal hemoglobin induc-
tion. The lack of bone marrow suppression of zileuton
gives it an additional advantage over HU in the manage-
ment of SCD.
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